- Pin
- ⏰ Just a Few Days Left!
🔥 The 12th Anniversary Celebration is Ending Soon — Don’t Miss Your Chance to Claim Rewards
🚀 Limited-Time Revelry #5 is Live
👉 Log in & play to win iPhone 16 Pro, MacBook Air and more: https://www.gate.com/activities/12th-anniversary
🏆 Draw for merch & send greetings on the Greeting Wall to win exclusive merch prizes
More Details: https://www.gate.com/announcements/article/44624
#Gate12Years#
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Round 2 Is On! 🏆 Round 1 winners will be announced on May 26!
Sign up now 👉 https://www.gate.com/questionnaire/6722
Registration Period 🕙 May 23, 03:00 AM – May 26, 04:00 PM UTC
✍️ Post daily from May 26 to June 1 and share a $300 prize pool based on your post quality!
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and
- 🎉 #Gate Post# Hits 50,000 Followers!
✨ To celebrate this amazing milestone, we're giving back to our incredible community!
🎁 4 Lucky Winners Will Each Receive $10 Points!
Join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your congratulations in the comments!
End at 18:00, May 25 (UTC)
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Is On!
👉 Post daily from May 19 to May 25 and share a $300 prize pool based on your post quality!
Join now: https://www.gate.io/questionnaire/6679
Registration deadline: May 20 10:00 UTC
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and their quality, ambassadors will be ranked and rewarded accordingly:
A-Level:
Post on
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.